-
1
-
-
0037126526
-
Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report
-
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143-3421 (2002).
-
(2002)
Circulation
, vol.106
, Issue.25
, pp. 3143-3421
-
-
-
2
-
-
84865627930
-
Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006
-
National Center for Health Statistics, MD, USA
-
Ervin RB: Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. National Health Statistics Reports. National Center for Health Statistics, MD, USA (2009).
-
(2009)
National Health Statistics Reports
-
-
Ervin, R.B.1
-
3
-
-
33747806291
-
Metabolic syndrome: The danger signal in atherosclerosis
-
Mathieu P, Pibarot P, Despres JP: Metabolic syndrome: the danger signal in atherosclerosis. Vasc. Health Risk Manag. 2(3), 285-302 (2006).
-
(2006)
Vasc. Health Risk Manag.
, vol.2
, Issue.3
, pp. 285-302
-
-
Mathieu, P.1
Pibarot, P.2
Despres, J.P.3
-
4
-
-
34548075248
-
Metabolic syndrome: Cardiovascular risk assessment and management
-
Wong ND: Metabolic syndrome: cardiovascular risk assessment and management. Am. J. Cardiovasc. Drugs 7(4), 259-272 (2007).
-
(2007)
Am. J. Cardiovasc. Drugs
, vol.7
, Issue.4
, pp. 259-272
-
-
Wong, N.D.1
-
5
-
-
26244432388
-
Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
-
Baigent C, Keech A, Kearney PM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267-1278 (2005).
-
(2005)
Lancet
, vol.366
, Issue.9493
, pp. 1267-1278
-
-
Baigent, C.1
Keech, A.2
Kearney, P.M.3
-
6
-
-
33947378229
-
Risk of cardiovascular events in patients at optimal values for combined lipid parameters
-
Stanek EJ, Sarawate C, Willey VJ, Charland SL, Cziraky MJ: Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr. Med. Res. Opin. 23(3), 553-563 (2007).
-
(2007)
Curr. Med. Res. Opin.
, vol.23
, Issue.3
, pp. 553-563
-
-
Stanek, E.J.1
Sarawate, C.2
Willey, V.J.3
Charland, S.L.4
Cziraky, M.J.5
-
7
-
-
56349154187
-
The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia
-
Fruchart JC, Sacks F, Hermans MP et al.: The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am. J. Cardiol. 102(10 Suppl.), 1K-34K (2008).
-
(2008)
Am. J. Cardiol.
, vol.102
, Issue.10 SUPPL.
-
-
Fruchart, J.C.1
Sacks, F.2
Hermans, M.P.3
-
8
-
-
15444375616
-
Rationale for combination therapy with statin drugs in the treatment of dyslipidemia
-
Ansell BJ: Rationale for combination therapy with statin drugs in the treatment of dyslipidemia. Curr. Atheroscler. Rep. 7(1), 29-33 (2005).
-
(2005)
Curr. Atheroscler. Rep.
, vol.7
, Issue.1
, pp. 29-33
-
-
Ansell, B.J.1
-
9
-
-
73849086222
-
Combination therapy of statins and fibrates in the management of cardiovascular risk
-
Fievet C, Staels B: Combination therapy of statins and fibrates in the management of cardiovascular risk. Curr. Opin. Lipidol. 20(6), 505-511 (2009).
-
(2009)
Curr. Opin. Lipidol.
, vol.20
, Issue.6
, pp. 505-511
-
-
Fievet, C.1
Staels, B.2
-
10
-
-
3142729178
-
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
-
Grundy SM, Cleeman JI, Merz CN et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110(2), 227-239 (2004).
-
(2004)
Circulation
, vol.110
, Issue.2
, pp. 227-239
-
-
Grundy, S.M.1
Cleeman, J.I.2
Merz, C.N.3
-
11
-
-
23744475368
-
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: Benefits versus risks
-
McKenney JM: Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. Am. J. Cardiol. 96(4A), 60E-66E (2005).
-
(2005)
Am. J. Cardiol.
, vol.96
, Issue.4 A
-
-
McKenney, J.M.1
-
12
-
-
15944410609
-
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
-
LaRosa JC, Grundy SM, Waters DD et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352(14), 1425-1435 (2005).
-
(2005)
N. Engl. J. Med.
, vol.352
, Issue.14
, pp. 1425-1435
-
-
Larosa, J.C.1
Grundy, S.M.2
Waters, D.D.3
-
14
-
-
0038236574
-
Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: A critical review of potential benefits and drawbacks
-
Farnier M: Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks. Am. J. Cardiovasc. Drugs 3(3), 169-178 (2003).
-
(2003)
Am. J. Cardiovasc. Drugs
, vol.3
, Issue.3
, pp. 169-178
-
-
Farnier, M.1
-
15
-
-
13144290929
-
Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: Fibrates, statins or both?
-
Tenenbaum A, Fisman EZ: Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both? Cardiovasc. Diabetol. 3, 10 (2004).
-
(2004)
Cardiovasc. Diabetol.
, vol.3
, pp. 10
-
-
Tenenbaum, A.1
Fisman, E.Z.2
-
16
-
-
33749536035
-
Atherogenic dyslipidemia in metabolic syndrome and Type 2 diabetes: Therapeutic options beyond statins
-
Tenenbaum A, Fisman EZ, Motro M, Adler Y: Atherogenic dyslipidemia in metabolic syndrome and Type 2 diabetes: therapeutic options beyond statins. Cardiovasc. Diabetol. 5, 20 (2006).
-
(2006)
Cardiovasc. Diabetol.
, vol.5
, pp. 20
-
-
Tenenbaum, A.1
Fisman, E.Z.2
Motro, M.3
Adler, Y.4
-
17
-
-
43749083758
-
Optimal management of combined dyslipidemia: What have we behind statins monotherapy?
-
Tenenbaum A, Fisman EZ, Motro M, Adler Y: Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Adv. Cardiol. 45, 127-153 (2008).
-
(2008)
Adv. Cardiol.
, vol.45
, pp. 127-153
-
-
Tenenbaum, A.1
Fisman, E.Z.2
Motro, M.3
Adler, Y.4
-
18
-
-
48549093490
-
National Lipid Association Taskforce on Non-HDL Cholesterol: The importance of non-HDL cholesterol reporting in lipid management
-
Blaha MJ, Blumenthal RS, Brinton EA, Jacobson TA; National Lipid Association Taskforce on Non-HDL Cholesterol: The importance of non-HDL cholesterol reporting in lipid management. J. Clin. Lipid. 2, 267-273 (2008).
-
(2008)
J. Clin. Lipid.
, vol.2
, pp. 267-273
-
-
Blaha, M.J.1
Blumenthal, R.S.2
Brinton, E.A.3
Jacobson, T.A.4
-
19
-
-
58249086417
-
Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk
-
Robinson JG, Wang S, Smith BJ, Jacobson TA: Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J. Am. Coll. Cardiol. 53(4), 316-322 (2009).
-
(2009)
J. Am. Coll. Cardiol.
, vol.53
, Issue.4
, pp. 316-322
-
-
Robinson, J.G.1
Wang, S.2
Smith, B.J.3
Jacobson, T.A.4
-
20
-
-
0036636769
-
Atorvastatin and micronized fenofibrate alone and in combination in Type 2 diabetes with combined hyperlipidemia
-
Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG: Atorvastatin and micronized fenofibrate alone and in combination in Type 2 diabetes with combined hyperlipidemia. Diabetes Care 25(7), 1198-1202 (2002).
-
(2002)
Diabetes Care
, vol.25
, Issue.7
, pp. 1198-1202
-
-
Athyros, V.G.1
Papageorgiou, A.A.2
Athyrou, V.V.3
Demitriadis, D.S.4
Kontopoulos, A.G.5
-
21
-
-
59049086841
-
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia
-
Goldberg AC, Bays HE, Ballantyne CM et al.: Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am. J. Cardiol. 103(4), 515-522 (2009).
-
(2009)
Am. J. Cardiol.
, vol.103
, Issue.4
, pp. 515-522
-
-
Goldberg, A.C.1
Bays, H.E.2
Ballantyne, C.M.3
-
22
-
-
13844272245
-
Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)
-
Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J: Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am. J. Cardiol. 95(4), 462-468 (2005).
-
(2005)
Am. J. Cardiol.
, vol.95
, Issue.4
, pp. 462-468
-
-
Grundy, S.M.1
Vega, G.L.2
Yuan, Z.3
Battisti, W.P.4
Brady, W.E.5
Palmisano, J.6
-
23
-
-
57149105884
-
Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A Phase 3, randomized, controlled study
-
Mohiuddin SM, Pepine CJ, Kelly MT et al.: Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a Phase 3, randomized, controlled study. Am. Heart J. 157(1), 195-203 (2009).
-
(2009)
Am. Heart J.
, vol.157
, Issue.1
, pp. 195-203
-
-
Mohiuddin, S.M.1
Pepine, C.J.2
Kelly, M.T.3
-
24
-
-
0037446467
-
Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome
-
Vega GL, Ma PT, Cater NB et al.: Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am. J. Cardiol. 91(8), 956-960 (2003).
-
(2003)
Am. J. Cardiol.
, vol.91
, Issue.8
, pp. 956-960
-
-
Vega, G.L.1
Ma, P.T.2
Cater, N.B.3
-
26
-
-
0035924635
-
Peroxisome proliferator-activated receptor-α activation and high-density lipoprotein metabolism
-
Fruchart JC: Peroxisome proliferator-activated receptor-α activation and high-density lipoprotein metabolism. Am. J. Cardiol. 88(12A), 24N-29N (2001).
-
(2001)
Am. J. Cardiol.
, vol.88
, Issue.12 A
-
-
Fruchart, J.C.1
-
27
-
-
26844431513
-
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: The bezafibrate lessons
-
Tenenbaum A, Motro M, Fisman EZ: Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc. Diabetol. 4, 14 (2005).
-
(2005)
Cardiovasc. Diabetol.
, vol.4
, pp. 14
-
-
Tenenbaum, A.1
Motro, M.2
Fisman, E.Z.3
-
28
-
-
77952422358
-
The effect of PPAR - A agonism on apolipoprotein metabolism in humans
-
Shah A, Rader DJ, Millar JS: The effect of PPAR-a agonism on apolipoprotein metabolism in humans. Atherosclerosis 210(1), 35-40 (2009).
-
(2009)
Atherosclerosis
, vol.210
, Issue.1
, pp. 35-40
-
-
Shah, A.1
Rader, D.J.2
Millar, J.S.3
-
29
-
-
70349342714
-
Effect of fibrates on lipid profiles and cardiovascular outcomes: A systematic review
-
962
-
Abourbih S, Filion KB, Joseph L et al.: Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am. J. Med. 122(10), 962 E1-E8 (2009).
-
(2009)
Am. J. Med.
, vol.122
, Issue.10
-
-
Abourbih, S.1
Filion, K.B.2
Joseph, L.3
-
31
-
-
18744384338
-
Efficacy and safety of rosuvastatin in treatment of dyslipidemia
-
McKenney JM: Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am. J. Health. Syst. Pharm. 62(10), 1033-1047 (2005).
-
(2005)
Am. J. Health. Syst. Pharm.
, vol.62
, Issue.10
, pp. 1033-1047
-
-
McKenney, J.M.1
-
32
-
-
0038645309
-
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial)
-
Jones PH, Davidson MH, Stein EA et al.: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am. J. Cardiol. 92(2), 152-160 (2003).
-
(2003)
Am. J. Cardiol.
, vol.92
, Issue.2
, pp. 152-160
-
-
Jones, P.H.1
Davidson, M.H.2
Stein, E.A.3
-
33
-
-
56749106312
-
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
-
Ridker PM, Danielson E, Fonseca FA et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359(21), 2195-2207 (2008).
-
(2008)
N. Engl. J. Med.
, vol.359
, Issue.21
, pp. 2195-2207
-
-
Ridker, P.M.1
Danielson, E.2
Fonseca, F.A.3
-
34
-
-
52949107622
-
Treatment of hyperlipidaemia with fenofibrate and related fibrates
-
Filippatos T, Milionis HJ: Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opin. Investig. Drugs 17(10), 1599-1614 (2008).
-
(2008)
Expert Opin. Investig. Drugs
, vol.17
, Issue.10
, pp. 1599-1614
-
-
Filippatos, T.1
Milionis, H.J.2
-
35
-
-
0031909536
-
Clinical pharmacokinetics of fibric acid derivatives (fibrates)
-
Miller DB, Spence JD: Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin. Pharmacokinet. 34(2), 155-162 (1998).
-
(1998)
Clin. Pharmacokinet.
, vol.34
, Issue.2
, pp. 155-162
-
-
Miller, D.B.1
Spence, J.D.2
-
36
-
-
58149181570
-
ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans
-
Zhu T, Awni WM, Hosmane B et al.: ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. J. Clin. Pharmacol. 49(1), 63-71 (2009).
-
(2009)
J. Clin. Pharmacol.
, vol.49
, Issue.1
, pp. 63-71
-
-
Zhu, T.1
Awni, W.M.2
Hosmane, B.3
-
37
-
-
33750595221
-
An assessment of statin safety
-
McKenney JM: An assessment of statin safety. Am. J. Manag. Care 12(11 Suppl.), S310-S317 (2006).
-
(2006)
Am. J. Manag. Care
, vol.12
, Issue.11 SUPPL.
-
-
McKenney, J.M.1
-
38
-
-
67249111853
-
Narrative review: Statin-related myopathy
-
Joy TR, Hegele RA: Narrative review: statin-related myopathy. Ann. Intern. Med. 150(12), 858-868 (2009).
-
(2009)
Ann. Intern. Med.
, vol.150
, Issue.12
, pp. 858-868
-
-
Joy, T.R.1
Hegele, R.A.2
-
39
-
-
77149180421
-
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia
-
Kostapanos MS, Milionis HJ, Elisaf MS: Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am. J. Cardiovasc. Drugs 10(1), 11-28 (2010).
-
(2010)
Am. J. Cardiovasc. Drugs
, vol.10
, Issue.1
, pp. 11-28
-
-
Kostapanos, M.S.1
Milionis, H.J.2
Elisaf, M.S.3
-
40
-
-
34248223741
-
Safety of rosuvastatin: Update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program
-
Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J: Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 107(4), 433-443 (2007).
-
(2007)
Cardiology
, vol.107
, Issue.4
, pp. 433-443
-
-
Shepherd, J.1
Vidt, D.G.2
Miller, E.3
Harris, S.4
Blasetto, J.5
-
41
-
-
0035337643
-
Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate
-
Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ: Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin. Pharmacol. Ther. 69(5), 340-345 (2001).
-
(2001)
Clin. Pharmacol. Ther.
, vol.69
, Issue.5
, pp. 340-345
-
-
Kyrklund, C.1
Backman, J.T.2
Kivisto, K.T.3
Neuvonen, M.4
Laitila, J.5
Neuvonen, P.J.6
-
42
-
-
11144354934
-
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
-
Schneck DW, Birmingham BK, Zalikowski JA et al.: The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. 75(5), 455-463 (2004).
-
(2004)
Clin. Pharmacol. Ther.
, vol.75
, Issue.5
, pp. 455-463
-
-
Schneck, D.W.1
Birmingham, B.K.2
Zalikowski, J.A.3
-
43
-
-
0037534010
-
Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance
-
DOI 10.1016/S0009-9236(03)00052-3
-
Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ: Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin. Pharmacol. Ther. 73(6), 538-544 (2003). (Pubitemid 37249124)
-
(2003)
Clinical Pharmacology and Therapeutics
, vol.73
, Issue.6
, pp. 538-544
-
-
Kyrklund, C.1
Backman, J.T.2
Neuvonen, M.3
Neuvonen, P.J.4
-
44
-
-
70349334010
-
Myopathy with statin-fibrate combination therapy: Clinical considerations
-
Jacobson TA: Myopathy with statin-fibrate combination therapy: clinical considerations. Nat. Rev. Endocrinol. 5(9), 507-518 (2009).
-
(2009)
Nat. Rev. Endocrinol.
, vol.5
, Issue.9
, pp. 507-518
-
-
Jacobson, T.A.1
-
46
-
-
30344436628
-
Statin/fibrate combination in patients with metabolic syndrome or diabetes: Evaluating the risks of pharmacokinetic drug interactions
-
Davidson MH: Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin. Drug Saf. 5(1), 145-156 (2006).
-
(2006)
Expert Opin. Drug Saf.
, vol.5
, Issue.1
, pp. 145-156
-
-
Davidson, M.H.1
-
47
-
-
11144239674
-
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
-
Jones PH, Davidson MH: Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am. J. Cardiol. 95(1), 120-122 (2005).
-
(2005)
Am. J. Cardiol.
, vol.95
, Issue.1
, pp. 120-122
-
-
Jones, P.H.1
Davidson, M.H.2
-
48
-
-
0037292311
-
An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers
-
Martin PD, Dane AL, Schneck DW, Warwick MJ: An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin. Ther. 25(2), 459-471 (2003).
-
(2003)
Clin. Ther.
, vol.25
, Issue.2
, pp. 459-471
-
-
Martin, P.D.1
Dane, A.L.2
Schneck, D.W.3
Warwick, M.J.4
-
49
-
-
67349119255
-
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A Phase 3 study
-
Jones PH, Davidson MH, Kashyap ML et al.: Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a Phase 3 study. Atherosclerosis 204(1), 208-215 (2009).
-
(2009)
Atherosclerosis
, vol.204
, Issue.1
, pp. 208-215
-
-
Jones, P.H.1
Davidson, M.H.2
Kashyap, M.L.3
-
50
-
-
77649209632
-
A Phase III study evaluating the efficacy and safety of 135 mg fenofibric acid (ABT-335) in combination with 5 mg rosuvastatin in patients with atherogenic dyslipidemia
-
Roth EM, Rosenson RS, Carlson DM et al.: A Phase III study evaluating the efficacy and safety of 135 mg fenofibric acid (ABT-335) in combination with 5 mg rosuvastatin in patients with atherogenic dyslipidemia. J. Am. Coll. Cardiol. 53(Suppl. A), A208 (2009).
-
(2009)
J. Am. Coll. Cardiol.
, vol.53
, Issue.SUPPL. A
-
-
Roth, E.M.1
Rosenson, R.S.2
Carlson, D.M.3
-
51
-
-
1842559795
-
Rosuvastatin and fenofibrate alone and in combination in Type 2 diabetes patients with combined hyperlipidaemia
-
Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K: Rosuvastatin and fenofibrate alone and in combination in Type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res. Clin. Pract. 64(2), 137-151 (2004).
-
(2004)
Diabetes Res. Clin. Pract.
, vol.64
, Issue.2
, pp. 137-151
-
-
Durrington, P.N.1
Tuomilehto, J.2
Hamann, A.3
Kallend, D.4
Smith, K.5
-
52
-
-
0036040929
-
Effects of fibrates on serum metabolic parameters
-
Elisaf M: Effects of fibrates on serum metabolic parameters. Curr. Med. Res. Opin. 18(5), 269-276 (2002).
-
(2002)
Curr. Med. Res. Opin.
, vol.18
, Issue.5
, pp. 269-276
-
-
Elisaf, M.1
-
53
-
-
0141794167
-
Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil)
-
Farnier M, Salko T, Isaacsohn JL, Troendle AJ, Dejager S, Gonasun L: Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). Am. J. Cardiol. 92(7), 794-797 (2003).
-
(2003)
Am. J. Cardiol.
, vol.92
, Issue.7
, pp. 794-797
-
-
Farnier, M.1
Salko, T.2
Isaacsohn, J.L.3
Troendle, A.J.4
Dejager, S.5
Gonasun, L.6
-
54
-
-
5144227019
-
The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy
-
Fazio S, Linton MF: The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr. Atheroscler. Rep. 6(2), 148-157 (2004).
-
(2004)
Curr. Atheroscler. Rep.
, vol.6
, Issue.2
, pp. 148-157
-
-
Fazio, S.1
Linton, M.F.2
-
55
-
-
34547687824
-
Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome
-
Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW: Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 30(8), 1945-1951 (2007).
-
(2007)
Diabetes Care
, vol.30
, Issue.8
, pp. 1945-1951
-
-
Rosenson, R.S.1
Wolff, D.A.2
Huskin, A.L.3
Helenowski, I.B.4
Rademaker, A.W.5
-
56
-
-
0036238785
-
A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients
-
Lemieux I, Laperriere L, Dzavik V, Tremblay G, Bourgeois J, Despres JP: A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. Atherosclerosis 162(2), 363-371 (2002).
-
(2002)
Atherosclerosis
, vol.162
, Issue.2
, pp. 363-371
-
-
Lemieux, I.1
Laperriere, L.2
Dzavik, V.3
Tremblay, G.4
Bourgeois, J.5
Despres, J.P.6
-
57
-
-
57349155535
-
Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia
-
Bays HE, Jones PH, Mohiuddin SM et al.: Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J. Clin. Lipid. 2, 426-435 (2008).
-
(2008)
J. Clin. Lipid.
, vol.2
, pp. 426-435
-
-
Bays, H.E.1
Jones, P.H.2
Mohiuddin, S.M.3
-
58
-
-
72049124300
-
Year two assessment of fenofibric acid and moderate-dose statin combination
-
Kipnes MS, Roth EM, Rhyne JM et al.: Year two assessment of fenofibric acid and moderate-dose statin combination. Clin. Drug Invest. 30(1), 51-61 (2010).
-
(2010)
Clin. Drug Invest.
, vol.30
, Issue.1
, pp. 51-61
-
-
Kipnes, M.S.1
Roth, E.M.2
Rhyne, J.M.3
-
59
-
-
28044452217
-
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): Randomised controlled trial
-
Keech A, Simes RJ, Barter P et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500), 1849-1861 (2005).
-
(2005)
Lancet
, vol.366
, Issue.9500
, pp. 1849-1861
-
-
Keech, A.1
Simes, R.J.2
Barter, P.3
-
60
-
-
64749095070
-
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with Type 2 diabetes and various components of the metabolic syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
-
Scott R, O'Brien R, Fulcher G et al.: Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with Type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 32(3), 493-498 (2009).
-
(2009)
Diabetes Care
, vol.32
, Issue.3
, pp. 493-498
-
-
Scott, R.1
O'brien, R.2
Fulcher, G.3
-
61
-
-
77953264127
-
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia - A randomized study
-
Roth EM, McKenney JM, Kelly MT et al.: Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia - a randomized study. Am. J. Cardiovasc. Drugs, 10(3), 175-186 (2010).
-
(2010)
Am. J. Cardiovasc. Drugs
, vol.10
, Issue.3
, pp. 175-186
-
-
Roth, E.M.1
McKenney, J.M.2
Kelly, M.T.3
-
62
-
-
78149438296
-
A Phase III study evaluating the efficacy and safety of 135 mg fenofibric acid (ABT-335) in combination with 5 mg rosuvastatin in patients with atherogenic dyslipidemia
-
Presented at, Orlando, FL, USA, 29-31 March
-
Roth EM, Rosenson RS, Carlson DM et al.: A Phase III study evaluating the efficacy and safety of 135 mg fenofibric acid (ABT-335) in combination with 5 mg rosuvastatin in patients with atherogenic dyslipidemia. Presented at: 58th Annual Scientific Session of the American College of Cardiology. Orlando, FL, USA, 29-31 March 2009.
-
(2009)
58th Annual Scientific Session of the American College of Cardiology
-
-
Roth, E.M.1
Rosenson, R.S.2
Carlson, D.M.3
-
63
-
-
77951704587
-
Effects of combination lipid therapy in Type 2 diabetes mellitus
-
Ginsberg HN, Elam MB, Lovato LC et al.: Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med. 362(17), 1563-1574 (2010).
-
(2010)
N. Engl. J. Med.
, vol.362
, Issue.17
, pp. 1563-1574
-
-
Ginsberg, H.N.1
Elam, M.B.2
Lovato, L.C.3
-
64
-
-
19344375593
-
Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome
-
Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch. Intern. Med. 165(10), 1154-1160 (2005).
-
(2005)
Arch. Intern. Med.
, vol.165
, Issue.10
, pp. 1154-1160
-
-
Tenenbaum, A.1
Motro, M.2
Fisman, E.Z.3
Tanne, D.4
Boyko, V.5
Behar, S.6
-
65
-
-
0033527030
-
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
-
Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
-
Rubins HB, Robins SJ, Collins D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341(6), 410-418 (1999).
-
(1999)
N. Engl. J. Med.
, vol.341
, Issue.6
, pp. 410-418
-
-
Rubins, H.B.1
Robins, S.J.2
Collins, D.3
-
66
-
-
66349088277
-
Relationships of HDL cholesterol, apoAI, and ApoA-II with homocysteine and creatinine in patients with Type 2 diabetes treated with fenofibrate
-
Taskinen MR, Sullivan DR, Ehnholm C et al.: Relationships of HDL cholesterol, apoAI, and ApoA-II with homocysteine and creatinine in patients with Type 2 diabetes treated with fenofibrate. Arterioscler. Thromb. Vasc. Biol. 29(6), 950-955 (2009).
-
(2009)
Arterioscler. Thromb. Vasc. Biol.
, vol.29
, Issue.6
, pp. 950-955
-
-
Taskinen, M.R.1
Sullivan, D.R.2
Ehnholm, C.3
-
67
-
-
77952708442
-
Effects of fibrates on cardiovascular outcomes: A systematic review and meta-analysis
-
Jun M, Foote C, Lv J et al.: Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375(9729), 1875-1884 (2010).
-
(2010)
Lancet
, vol.375
, Issue.9729
, pp. 1875-1884
-
-
Jun, M.1
Foote, C.2
Lv, J.3
-
68
-
-
11344279659
-
C-reactive protein levels and outcomes after statin therapy
-
Ridker PM, Cannon CP, Morrow D et al.: C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352(1), 20-28 (2005).
-
(2005)
N. Engl. J. Med.
, vol.352
, Issue.1
, pp. 20-28
-
-
Ridker, P.M.1
Cannon, C.P.2
Morrow, D.3
-
69
-
-
78149454768
-
-
Kowa Pharmaceuticals America Inc., AL, USA
-
LIVALO®, prescribing information. Kowa Pharmaceuticals America Inc., AL, USA (2009).
-
(2009)
LIVALO®, Prescribing Information
-
-
-
70
-
-
0141988934
-
Pitavastatin: Efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor
-
Kajinami K, Takekoshi N, Saito Y: Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc. Drug Rev. 21(3), 199-215 (2003).
-
(2003)
Cardiovasc. Drug Rev.
, vol.21
, Issue.3
, pp. 199-215
-
-
Kajinami, K.1
Takekoshi, N.2
Saito, Y.3
|